ArticleBone marrow transplantation2018
Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation.
Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk factors for ocular graft-versus-host disease: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Bone marrow transplantation · 2019Pooled it
- Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Long-term clinical outcomes in chronic ocular graft-versus-host disease: a retrospective cohort study.Eye (London, England) · 2026Article
- Patient-reported outcomes in chronic GVHD: instruments, clinical utility, and survivorship integration.Journal of patient-reported outcomes · 2026Review
- Exosomes in ocular graft-versus-host disease: an overview.International journal of ophthalmology · 2026Review
- Ocular Immersion Hydrotherapy Effectively Alleviate Symptoms and Signs of Severe Dry Eye Secondary to Ocular Graft-Versus-Host Disease in a Short Term.Case reports in medicine · 2026Article
- Tear fluid participates in systemic immunity.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Tear fluid derived extracellular vesicles for new biomarker discovery.The ocular surface · 2025Review
- Application of lacrimal gland ultrasonography in the evaluation of chronic ocular graft-versus-host-disease.Frontiers in immunology · 2025Article
- Epidemiology and risk factors for the development of cicatrizing conjunctivitis in chronic ocular graft-versus-host disease.The ocular surface · 2024Article
- Ophthalmic Manifestations in Patients with Blood Malignancies.Hematology reports · 2024Review
- [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- MSCohi-O lenses for long-term retention of mesenchymal stem cells on ocular surface as a therapeutic approach for chronic ocular graft-versus-host disease.Stem cell reports · 2023Article
- Corneal Descemetocele Management with Multi-Layer Amniotic Membrane Transplantation in an Ocular Graft-versus-Host Disease Case.Medicina (Kaunas, Lithuania) · 2023Article
- [Chinese expert consensus on ocular chronic graft-versus-host disease (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- A brief account on ocular graft versus host disease.Indian journal of ophthalmology · 2023Review
- A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors.BMC ophthalmology · 2023Article
- Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.Frontiers in medicine · 2023Review
- Recent advances in ocular graft-versus-host disease.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients treated with allogeneic stem cell transplantation (allo-SCT) often develop ocular complications. To investigate the ocular findings in young long-term survivors after allo-SCT without TBI, we examined 96 patients more than 5 years after transplantation. All patients were under 30 years of age at transplantation. The mean follow-up time was 16.8 years (range 6.0-26.1 years). The study was a part of the Norwegian Allo Survivorship Study investigating health impairments in young survivors after allo-SCT. Ophthalmological examination included visual acuity, tear break-up time, corneal fluorescein staining, Schirmer I test, tear film osmolarity, biomicroscopy and dilated ophthalmoscopy. In patients with known systemic chronic GVHD (cGVHD), ocular GVHD (oGVHD) diagnosed by clinical examination was compared with diagnosis using National Institutes of Health (NIH) or International Chronic Ocular Graft-vs-Host-Disease (ICCGVHD) Consensus Group criteria. We diagnosed dry eye disease (DED) in 52 patients (54%), cataract in 3 patients (3%) and retinopathy in 1 patient (1%). Systemic cGVHD was a risk factor for DED (OR 4.40, CI 1.33-14.56, p = 0.02). Comparison of diagnostic criteria suggests that the more stringent ICCGVHD criteria can better differentiate DED from oGVHD after allo-SCT as compared with the NIH criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.